Inspiremd reports fourth quarter and full year 2024 financial results

Miami, march 12, 2025 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended december 31, 2024. recent business highlights: engaged with the u.s. food and drug administration (fda) on the premarket approval (pma) application for the cguard prime carotid stent system in the u.s. ahead of an anticipated first half 2025 approval announced approval of and enrolled first patients in the cguardians ii pivotal study of the cguard prime carotid stent system for use during tcar procedures established headquarters in miami, florida, to optimally support the anticipated u.s. commercial launch of cguard prime in the first half of 2025, if approved achieved quarterly revenue and unit records of $1.95m and 3.5k respectively in served markets marvin slosman, ceo of inspiremd, commented: “2024 was a year of tremendous progress at inspiremd.
NSPR Ratings Summary
NSPR Quant Ranking